World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
44
Citations
10095
World Ranking
4756
National Ranking
401

Best Publications

  • Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

    Sheena McCormack;David T. Dunn;Monica Desai;David I. Dolling

  • Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    Alison J Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  • Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.

    Cormac Cosgrove;James E. Ussher;Andri Rauch;Kathleen Gärtner

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

    J Frater;K J Ewer;A Ogbe;M Pace

  • Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans.

    Kathleen B. Yates;Kathleen B. Yates;Pierre Tonnerre;Pierre Tonnerre;Genevieve E. Martin;Genevieve E. Martin;Ulrike Gerdemann

  • Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men.

    Julie Fox;Peter J White;Peter J White;Neil Macdonald;Jonathan Weber

  • Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

    Nicholas I. Paton;Ruth L. Goodall;David T. Dunn;Samuel Franzen

  • Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.

    Matthias Hoffmann;Matthias Hoffmann;Nikos Pantazis;Genevieve E. Martin;Stephen Hickling

  • Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

    Jean-Michel Molina;Kathleen Squires;Paul E Sax;Pedro Cahn

  • Alterations in T and B cell function persist in convalescent COVID-19 patients.

    Halima A Shuwa;Tovah N Shaw;Sean B Knight;Kelly Wemyss

  • Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

    Unknown

  • Exploring Perceived Barriers and Facilitators of PrEP Uptake among Young People in Uganda, Zimbabwe, and South Africa

    Richard Muhumuza;Andrew Sentoogo Ssemata;Ayoub Kakande;Nadia Ahmed

  • Sexual transmission of HIV-1.

    Julie Fox;Sarah Fidler

  • Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

    S Fidler;W Stöhr;M Pace;L Dorrell

  • Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial.

    Julie Fox;Barry Peters;Manyu Prakash;Jose Arribas

  • Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining

    Thomas J. Scriba;Marco Purbhoo;Cheryl L. Day;Nicola Robinson

  • An overview of the relative risks of different sexual behaviours on HIV transmission.

    Olamide Dosekun;Julie Fox

  • Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

    Nicholas I Paton;Nicholas I Paton;Wolfgang Stöhr;Alejandro Arenas-Pinto;Martin Fisher

  • Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

    José M. Gatell;Lambert Assoumou;Graeme Moyle;Laura Waters

  • BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022

    Unknown

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: